189 related articles for article (PubMed ID: 16110135)
21. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Parvinen LM; Hahka-Kemppinen M; Korpela M; Kumpulainen E
Melanoma Res; 2000 Jun; 10(3):237-41. PubMed ID: 10890377
[TBL] [Abstract][Full Text] [Related]
22. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer.
Rich T; Innominato PF; Boerner J; Mormont MC; Iacobelli S; Baron B; Jasmin C; Lévi F
Clin Cancer Res; 2005 Mar; 11(5):1757-64. PubMed ID: 15755997
[TBL] [Abstract][Full Text] [Related]
23. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy.
Bozcuk H; Uslu G; Samur M; Yildiz M; Ozben T; Ozdoğan M; Artaç M; Altunbaş H; Akan I; Savaş B
Cytokine; 2004 Jul 21-Aug 7; 27(2-3):58-65. PubMed ID: 15242694
[TBL] [Abstract][Full Text] [Related]
24. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
[TBL] [Abstract][Full Text] [Related]
25. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study.
Tartour E; Deneux L; Mosseri V; Jaulerry C; Brunin F; Point D; Validire P; Dubray B; Fridman WH; Rodriguez J
Cancer; 1997 Apr; 79(7):1401-8. PubMed ID: 9083163
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
27. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
Ugurel S; Rappl G; Tilgen W; Reinhold U
J Clin Oncol; 2001 Jan; 19(2):577-83. PubMed ID: 11208853
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
29. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
31. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
Musto P; Matera R; Minervini MM; Checchia-de Ambrosio C; Bodenizza C; Falcone A; Carotenuto M
Haematologica; 1994; 79(3):265-8. PubMed ID: 7926977
[TBL] [Abstract][Full Text] [Related]
32. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.
Schmidt H; Bastholt L; Geertsen P; Christensen IJ; Larsen S; Gehl J; von der Maase H
Br J Cancer; 2005 Aug; 93(3):273-8. PubMed ID: 16052222
[TBL] [Abstract][Full Text] [Related]
33. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
[TBL] [Abstract][Full Text] [Related]
34. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma.
Nemunaitis J; Fong T; Shabe P; Martineau D; Ando D
Cancer Invest; 2001; 19(3):239-47. PubMed ID: 11338880
[TBL] [Abstract][Full Text] [Related]
35. [Influence of erythropoietin on immunological system of patients with chronic renal failure].
Debska-Slizień A; Rutkowski B; Manitius J; Zdrojewski Z; Szołkiewicz M; Bułło B; Lizakowski S; Myśliwska J; Myśliwski A; Bryl E; Trzonkowski P; Bakowska A; Rachoń D
Pol Merkur Lekarski; 2003 Oct; 15(88):326-7; discussion 327-9. PubMed ID: 14974359
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes.
Alexandrakis M; Coulocheri S; Xylouri I; Ganotakis E; Eliakis P; Karkavitsas N; Eliopoulos GD
Haematologia (Budap); 1998; 29(1):13-24. PubMed ID: 9704253
[TBL] [Abstract][Full Text] [Related]
37. Serum angiogenin levels predict treatment response in patients with stage IV melanoma.
Vihinen P; Kallioinen M; Vuoristo MS; Ivaska J; Syrjänen KJ; Hahka-Kemppinen M; Kellokumpu-Lehtinen PL; Pyrhönen SO
Clin Exp Metastasis; 2007; 24(7):567-74. PubMed ID: 17762972
[TBL] [Abstract][Full Text] [Related]
38. Low-dose erythropoietin aggravates endotoxin-induced organ damage in conscious rats.
Wu WT; Hu TM; Lin NT; Subeq YM; Lee RP; Hsu BG
Cytokine; 2010 Feb; 49(2):155-62. PubMed ID: 20004111
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.
Karabulut S; Afsar ÇU; Karabulut M; Alış H; Kılıc L; Çikot M; Yasasever CT; Aykan NF
J Gastrointest Cancer; 2016 Mar; 47(1):47-54. PubMed ID: 26637231
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
Bachelot T; Ray-Coquard I; Menetrier-Caux C; Rastkha M; Duc A; Blay JY
Br J Cancer; 2003 Jun; 88(11):1721-6. PubMed ID: 12771987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
